Cite
HARVARD Citation
Huynh, C. et al. (2021). A Multipurpose First‐in‐Human Study With the Novel CXCR7 Antagonist ACT‐1004‐1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker. Clinical pharmacology & therapeutics. 109 (6), pp. 1648-1659. [Online].